Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/cargo-therapeutics-inc">Cargo Therapeutics</a> is a clinical-stage biotechnology company that was focused on developing next-generation CAR T-cell therapies for cancer. Its lead candidate, firicabtagene autoleucel (firi-cel or CRG-022), targeted CD22 in patients with large B-cell lymphoma (LBCL) who had failed prior CD19-directed CAR T-cell therapy.</li>
  <li>In a significant setback, the company discontinued the pivotal Phase 2 trial of firi-cel in early 2025 due to a lack of durable responses and safety concerns. This event led to a halt of all research and development activities, a significant workforce reduction of approximately 90%, and a change in executive leadership.</li>
  <li>Following the clinical trial failure and subsequent restructuring, <a href="https://smartkarma.com/entities/cargo-therapeutics-inc">Cargo Therapeutics</a> entered into a definitive agreement to be acquired by Concentra Biosciences in mid-2025. The acquisition marks the culmination of the company's journey as a standalone entity, shifting shareholder value to the cash buyout price and potential proceeds from contingent value rights (CVRs).</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Cargo Therapeutics is a clinical-stage biotechnology company that was focused on developing next-generation CAR T-cell therapies for cancer. Its lead candidate, firicabtagene autoleucel (firi-cel or CRG-022), targeted CD22 in patients with large B-cell lymphoma (LBCL) who had failed prior CD19-directed CAR T-cell therapy.
  In a significant setback, the company discontinued the pivotal Phase 2 trial of firi-cel in early 2025 due to a lack of durable responses and safety concerns. This event led to a halt of all research and development activities, a significant workforce reduction of approximately 90%, and a change in executive leadership.
  Following the clinical trial failure and subsequent restructuring, Cargo Therapeutics entered into a definitive agreement to be acquired by Concentra Biosciences in mid-2025. The acquisition marks the culmination of the company's journey as a standalone entity, shifting shareholder value to the cash buyout price and potential proceeds from contingent value rights (CVRs).
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Cargo Therapeutics (CRGX US) - Aug 2026

United States

Cargo Therapeutics, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer patients. Cargo Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Cargo Therapeutics (CRGX US) - Aug 2026

Cargo Therapeutics is a clinical-stage biotechnology company that was focused on developing next-generation CAR T-cell therapies for cancer....

αSK Primers